Cortez Dolores M, Feldman Marc D, Mummidi Srinivas, Valente Anthony J, Steffensen Bjorn, Vincenti Matthew, Barnes Jeffrey L, Chandrasekar Bysani
Department of Veterans Affairs South Texas Veterans Health Care System, The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3356-65. doi: 10.1152/ajpheart.00928.2007. Epub 2007 Oct 5.
Matrix metalloproteinases (MMPs) degrade collagen and mediate tissue remodeling. The novel cytokine IL-17 is expressed during various inflammatory conditions and modulates MMP expression. We investigated the effect of IL-17 on MMP-1 expression in primary human cardiac fibroblasts (HCF) and delineated the signaling pathways involved. HCF were treated with recombinant human IL-17. MMP-1 expression was analyzed by Northern blotting, RT-quantitative PCR, Western blotting, and ELISA; transcriptional induction and transcription factor binding by EMSA, ELISA, and reporter assay; and p38 MAPK and ERK1/2 activation by protein kinase assays and Western blotting. Signal transduction pathways were investigated using pharmacological inhibitors, small interfering RNA (siRNA), and adenoviral dominant-negative expression vectors. IL-17 stimulated MMP-1 gene transcription, net mRNA levels, protein, and promoter-reporter activity in HCF. This response was blocked by IL-17 receptor-Fc chimera and IL-17 receptor antibodies, but not by IL-6, TNF-alpha, or IL-1beta antibodies. IL-17-stimulated type I collagenase activity was inhibited by the MMP inhibitor GM-6001 and by siRNA-mediated MMP-1 knockdown. IL-17 stimulated activator protein-1 [AP-1 (c-Fos, c-Jun, and Fra-1)], NF-kappaB (p50 and p65), and CCAAT enhancer-binding protein (C/EBP)-beta DNA binding and reporter gene activities, effects attenuated by antisense oligonucleotides, siRNA-mediated knockdown, or expression of dominant-negative signaling proteins. Inhibition of AP-1, NF-kappaB, or C/EBP activation attenuated IL-17-stimulated MMP-1 expression. IL-17 induced p38 MAPK and ERK1/2 activation, and inhibition by SB-203580 and PD-98059 blunted IL-17-mediated transcription factor activation and MMP-1 expression. Our data indicate that IL-17 induces MMP-1 in human cardiac fibroblasts directly via p38 MAPK- and ERK-dependent AP-1, NF-kappaB, and C/EBP-beta activation and suggest that IL-17 may play a critical role in myocardial remodeling.
基质金属蛋白酶(MMPs)可降解胶原蛋白并介导组织重塑。新型细胞因子白细胞介素-17(IL-17)在多种炎症状态下表达,并调节MMP的表达。我们研究了IL-17对原代人心脏成纤维细胞(HCF)中MMP-1表达的影响,并阐明了其中涉及的信号通路。用重组人IL-17处理HCF。通过Northern印迹、逆转录定量PCR、Western印迹和酶联免疫吸附测定(ELISA)分析MMP-1的表达;通过电泳迁移率变动分析(EMSA)、ELISA和报告基因测定分析转录诱导和转录因子结合;通过蛋白激酶测定和Western印迹分析p38丝裂原活化蛋白激酶(MAPK)和细胞外信号调节激酶1/2(ERK1/2)的激活。使用药理学抑制剂、小干扰RNA(siRNA)和腺病毒显性阴性表达载体研究信号转导通路。IL-17刺激HCF中MMP-1基因转录、净mRNA水平、蛋白质及启动子-报告基因活性。IL-17受体-Fc嵌合体和IL-17受体抗体可阻断这种反应,但IL-6、肿瘤坏死因子-α(TNF-α)或白细胞介素-1β(IL-1β)抗体则不能。MMP抑制剂GM-6001和siRNA介导的MMP-1敲低可抑制IL-17刺激的I型胶原酶活性。IL-17刺激激活蛋白-1 [AP-1(c-Fos、c-Jun和Fra-1)]、核因子-κB(NF-κB,p50和p65)以及CCAAT增强子结合蛋白(C/EBP)-β的DNA结合及报告基因活性,反义寡核苷酸、siRNA介导的敲低或显性阴性信号蛋白的表达可减弱这些效应。抑制AP-1、NF-κB或C/EBP的激活可减弱IL-17刺激的MMP-1表达。IL-17诱导p38 MAPK和ERK1/2激活,SB-203580和PD-98059的抑制作用可减弱IL-17介导的转录因子激活和MMP-1表达。我们的数据表明,IL-17通过p38 MAPK和ERK依赖的AP-1、NF-κB和C/EBP-β激活直接诱导人心脏成纤维细胞中的MMP-1,提示IL-17可能在心肌重塑中起关键作用。